Hexarelin
Research OnlyAlso known as: Examorelin, HEX, Growth Hormone Releasing Hexapeptide, MF-6003, EP-23905
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.
Research Statistics
Moderate clinical body led primarily by Italian research groups; cardioprotective mechanism via CD36 is well-characterized but global trial diversity is limited.
Research Dossier
Overview
What is Hexarelin and what does the research say?
Mechanism of Action
Hexarelin is the most potent synthetic growth hormone secretagogue, acting primarily through the ghrelin receptor (GHS-R1a). Unique among GHRPs, it also exhibits GH-independent cardioprotective effects via CD36 receptor binding.
How It Works (Simplified)
Hexarelin triggers powerful GH release but with a critical limitation - rapid desensitization:
Binds GHS-R1a on pituitary somatotrophs, triggering calcium release and potent GH secretion - 2-3x stronger than GHRP-6.
Uniquely binds CD36 on cardiomyocytes, activating PPAR-gamma and anti-apoptotic pathways independent of GH release.
High receptor affinity causes rapid receptor internalization - GH response drops 50-80% within one week of daily dosing.
Minimal cortisol/prolactin elevation compared to GHRP-6/GHRP-2, though less selective than ipamorelin.
Scientific Pathways
GHS-R1a Signaling (Growth Hormone Release)
Hexarelin → GHS-R1a → Gq/G11 → Phospholipase C → IP3 → Ca2+ release
↓
GH vesicle exocytosisCD36 Cardiac Pathway (Cardioprotection)
Hexarelin → CD36 binding → PPAR-gamma activation → Anti-apoptotic signaling
↓
Reduced ischemia-reperfusion injuryKey Research: Ghigo E et al. (Turin, 1994) established hexarelin as most potent GHRP in human studies. PMID:7806864
Important Limitations
- Rapid desensitization (4-7 days) ended pharmaceutical development
- Cardioprotective effects primarily demonstrated in animal models
- No sustained IGF-1 elevation achievable with chronic dosing
- Long-term safety data limited due to desensitization preventing chronic exposure
- Not approved by any regulatory agency for therapeutic use
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on human studies: GH peak occurs 15-30 minutes after subcutaneous or IV administration. GH response is approximately 2x greater than GHRP-6. Single-dose effects are potent and reliable.
Initial doses maintain strong GH response. Subcutaneous administration achieves 85-95% of IV GH response. Cardioprotective effects may occur with each dose independent of GH status.
Desensitization begins. GH response decreases 50-80% from initial levels. No sustained IGF-1 elevation achieved. This rapid tolerance ended pharmaceutical development.
Continued daily dosing produces minimal GH response. Recovery of sensitivity requires extended washout period. This desensitization profile makes hexarelin unsuitable for chronic therapy.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Hexarelin product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Hexarelin with other peptides. Based on published research and mechanistic considerations.
Tesamorelin
SynergisticGHRH+GHRP synergy - tesamorelin (GHRH) amplifies hexarelin's (GHRP) GH-releasing effect. However, hexarelin's rapid desensitization limits practical use of this combination.
Sermorelin
SynergisticClassic GHRH+GHRP synergy. Sermorelin (GHRH) and hexarelin (GHRP) produce greater GH release than either alone.
BPC-157
CompatibleDifferent mechanisms - hexarelin for GH release, BPC-157 for tissue repair. No known interactions.
GHRP-6
AvoidBoth are GHRPs acting on the same receptor (GHS-R1a). Combining provides no additional benefit and hexarelin desensitizes faster than GHRP-6.
GHRP-2
AvoidBoth are GHRPs targeting GHS-R1a. No benefit to combining as they share mechanism. Use one or the other.
Ipamorelin
AvoidBoth GHRPs acting on same receptor. Ipamorelin is more selective with less desensitization; combining offers no advantage.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Hexarelin
Hexarelin Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
HMG
Human Menopausal Gonadotropin, Menotropins, hMG +4 more
A urinary-derived glycoprotein hormone preparation containing both FSH and LH in approximately 1:1 ratio, FDA-approved for female infertility (ovulation induction, ART) and male hypogonadotropic hypogonadism. First used clinically in 1961 by Bruno Lunenfeld, HMG enabled the birth of the first American IVF baby in 1981 and remains a cornerstone of fertility medicine with over 60 years of clinical experience. Highly purified preparations (HP-hMG) demonstrate comparable or slightly superior live birth rates compared to recombinant FSH in IVF.
IGF-1 LR3
Long R3 IGF-1, LR3-IGF-1, Insulin-like Growth Factor 1 Long R3
A modified form of IGF-1 with an extended half-life due to reduced binding protein affinity. Used primarily in research for muscle growth and metabolic effects. Not approved for human use; significant safety concerns exist.
Kisspeptin
KISS1, Metastin, Kisspeptin-54 +3 more
An endogenous neuropeptide that serves as the master regulator of reproductive function. Acts upstream of GnRH to control puberty, fertility, and the menstrual cycle. Under clinical investigation as a safer IVF trigger and treatment for hypothalamic amenorrhea. Pioneering research led by Imperial College London.